Novo Nordisk Pharmaceutical 00169406012 - McKesson Medical-Surgical
![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200095 "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
Diabetes Medicine Savings & Support | NovoCare®
Pharmaceutical Stocks Eye A Big New Market For Their Diabetes Drugs: Obesity | Investor's Business Daily
![Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management](http://photos.prnewswire.com/prnfull/20141224/166096 "Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management")
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
Novo Nordisk Beats Appeal in Diabetes Drug Cancer Litigation
Liraglutide – Next-Generation Antidiabetic Medication - Clinical Trials Arena
Rx Item-Victoza Pen 0.6Mg 0.1 Inj 2 By Novo Nordisk Pharm
Paula Deen's Pharma Deal Suspended by Novo Nordisk - Eater
A package of Victoza (Liraglutide) injectors, manufactured by Novo Nordisk, prescription pharmaceuticals photographed in a pharmacy Stock Photo - Alamy
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QKOPLCUOOVIV5EFKGE7WWNSN3U.jpg "U.S. experts recommend weight-loss drugs for obese children | Reuters")
U.S. experts recommend weight-loss drugs for obese children | Reuters
Mixed reaction to Novo Nordisk obesity trial - PMLiVE
Rx Item-Victoza Pen 0.6Mg 0.1 Inj 3 By Novo Nordisk Pharm
A package of Victoza (Liraglutide) injectors, manufactured by Novo Nordisk, prescription pharmaceuticals photographed in a pharmacy Stock Photo - Alamy
Victoza Novo Nordisk A/S injektionsvæske, opløsning i fyldt pen 6 mg/ml
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Novo Nordisk targets Mexico for anti-obesity drug
Novo Nordisk Won't Be Pursuing Victoza for Type 1 Diabetes
Novo Nordisk Cuts Guidance as U.S. Challenges Intensify - WSJ
